Joint therapy

• US 20060045904A1
• Filed: 08/22/2005
• Published: 03/02/2006
• Est. Priority Date: 08/20/2004
• Status: Abandoned Application

• Current Assignee: Barry Aronson
• Original Assignee: Barry Aronson
• Inventors: Aronson, Barry
• Application Number:
  US11/208,908
• Publication Number:
  US 20060045904A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for synergistically treating a joint of an animal, including introducing a cushioning agent into a joint; and introducing an enzyme or hormone adapted to stimulate cartilage production into the joint. The joint may be subjected to a compression regimen following injection of the cushioning agent and enzyme/hormone. Alternatively, the invention may include a composition for synergistically treating a joint of an animal, comprising a viscous cushioning material adapted to be introduced within a joint space to provide cushioning for the joint, and hormones dispersed through the cushioning material, the hormones operable to increase cartilage production.

Claims

1. A composition for treating a joint of an animal, including:

a cushioning agent adapted to be injected into a joint; and

,

a hormone adapted to stimulate cartilage production.

2. The composition as recited in claim 1, wherein the cushioning material comprises a hyaluronic acid compound.

3. The composition as recited in claim 1, wherein the hormone is selected from the group consisting of insulin-like growth factors, insulin, and molecules that bind to insulin-like growth factor binding proteins.

4. A method of treating a joint of an animal, comprising the steps of:

introducing a cushioning agent into the joint space; and

,

introducing an hormone into the joint space, the hormone being operable to stimulate cartilage production, whereby both agents act synergistically to treat the joint.

5. The method as recited in claim 4, wherein the cushioning agent comprises a hyaluronic acid compound.

6. The method as recited in claim 5, further comprising the step of:

subjecting the joint to a compression regimen after the introduction of the cushioning agent and the hormone, whereby the cushioning agent, the hormone, and the compression regimen act synergistically to treat the joint.

7. The method as recited in claim 6, where in the hormone is an insulin-like growth factor.

8. The method as recited in claim 7, wherein the insulin-like growth factor is contained in a doped plate that is adapted for introduction into the joint.

9. The method as recited in claim 8, wherein the insulin-like growth factor is in a protracted-release form.

10. The method as recited in claim 9, wherein the doped plate is at least partially made of a material that is biologically absorbable.

11. The method as recited in claim 10, wherein the doped plate is at least partially made of collagen or fibrin.

12. The method as recited in claim 4, further comprising the step of:

subjecting the joint to a compression regimen after the introduction of the cushioning agent and the hormone, whereby the cushioning agent, the hormone, and the compression regimen act synergistically to treat the joint.

13. The method as recited in claim 12, wherein the hormone is an insulin-like growth factor.

14. The method as recited in claim 12, wherein the insulin-like growth factor is contained in a doped plate that is adapted for introduction into the joint.

15. The method as recited in claim 14, wherein the insulin-like growth factor is in a protracted-release form.

16. A composition for synergistically treating a joint of an animal, comprising:

a viscous cushioning material adapted to be introduced within a joint space to provide cushioning for the joint, and,

hormones dispersed through the cushioning material, the hormones operable to increase cartilage production.

17. The composition as recited in claim 16, wherein the hormone is selected from the group consisting of insulin-like growth factors, insulin, and molecules that bind insulin-like growth factor binding proteins.

18. The composition as recited in claim 16, wherein the composition is a gel in vivo.

19. The composition as recited in claim 16, wherein the hormone is in a protracted release form.

20. The composition as recited in claim 16, wherein,

the cushioning material is selected from the group consisting of collagen, fibrin, hyaluronic acid compounds, and,

the hormone is selected from the group consisting of:

insulin-like growth factors, insulin, and molecules that bind insulin-like growth factor binding proteins.